Molecular backgrounds of age-related osteoporosis from mouse genetics approaches

Reviews in Endocrine and Metabolic Disorders

Volumn 7, Issue 1-2, 2006, Pages 17-22

  Kawaguchi, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Insulin receptor substrate (IRS); Klotho; Osteoporosis; PPAR

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; AGING; BONE MASS; CATABOLISM; CELL DIFFERENTIATION; HETEROZYGOSITY; HUMAN; MOLECULAR DYNAMICS; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; GLUCURONIDASE; MICE; MODELS, BIOLOGICAL; OSTEOPOROSIS; PPAR GAMMA; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 33846025976     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-006-9011-3     Document Type: Review

References (48)

1. Bullamore JR, Gallagher JC, Wilkinson R, Nordin BE, Marshall DH. Effect of age on calcium absorption. Lancet 1970;12:535-7.
2. Gallagher JC, Riggs BL, Eisman J, Hamstra A, Arnaud SB, DeLuca HF. Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients. J Clin Invest 1979;64:729-36.
3. Horst RL, Goff JP, Reinhardt TA. Advancing age results in reduction of intestinal and bone 1,25-dihydroxyvitamin D receptor. Endocrinology 1990;126:1053-7.
4. Wood RJ, Fleet JC, Cashman K, Bruns ME, Deluca HF. Intestinal calcium absorption in the aged rat: evidence of intestinal resistance to 1,25(OH)2 vitamin D. Endocrinology 1998;139:3843-8.
5. Slovik DM, Adams JS, Neer R, Potts JT Jr. Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients. N Engl J Med 1981;305:372-4.
6. Ledger GA, Burritt MF, Kao PC, O'Fallon WM, Riggs BL, Khosla S. Abnormalities of parathyroid hormone secretion in elderly women that are reversible by short term therapy with 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab 1994;79:211-6.
7. Haden ST, Brown EM, Hurwitz S, Scott J, El-Hajj Fuleihan G. The effects of age and gender on parathyroid hormone dynamics. Clin Endocrinol (Oxf) 2000;52:329-38.
8. Cummings SR, Browner WS, Bauer D, Stone K, Ensrud K, Jamal S, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group. N Engl J Med 1998;339:733-8.
9. Christiansen M, Kveiborg M, Kassem M, Clark BF, Rattan SI. CBFA1 and topoisomerase I mRNA levels decline during cellular aging of human trabecular osteoblasts. J Gerontol A Biol Sci Med Sci 2000;55:B194-200.
10. Nicolas V, Prewett A, Bettica P, Mohan S, Finkelman RD, Baylink DJ, et al. Age-related decreases in insulin-like growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J Clin Endocrinol Metab 1994;78:1011-6.
11. Rosen CJ. Growth hormone, insulin-like growth factors, and the senescent skeleton: Ponce de Leon's Fountain revisited? J Cell Biochem 1994;56:348-56.
12. Sugimoto T, Nishiyama K, Kuribayashi F, Chihara K. Serum levels of insulin-like growth factor (IGF) I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. J Bone Miner Res 1997;12:1272-9.
13. Kodama Y, Takeuchi Y, Suzawa M, Fukumoto S, Murayama H, Yamato H, et al. Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice (SAMP6): relationship to osteopenia with enhanced adipogenesis. J Bone Miner Res 1998;13:1370-7.
14. Pfeilschifter J, Diel I, Scheppach B, Bretz A, Krempien R, Erdmann J, et al. Concentration of transforming growth factor beta in human bone tissue: relationship to age, menopause, bone turnover, and bone volume. J Bone Miner Res 1998;13:716-30.
15. Fleet JC, Cashman K, Cox K, Rosen V. The effects of aging on the bone inductive activity of recombinant human bone morphogenetic protein-2. Endocrinology 1996;137:4605-10.
16. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Sugi T, Utsugi T, et al: Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997;390:45-51.
17. Kawaguchi H, Manabe N, Miyaura C, Chikuda H, Nakamura K, Kuro-o M. Independent impairment of osteoblast and osteoclast differentiation in klotho mouse exhibiting low-turnover osteopenia. J Clin Invest 1999;104:229-37.
18. Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, Nagai R, et al. Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 2000;167:2625-31.
19. Takahashi Y, Kuro-o M, Ishikawa F. Aging mechanisms. Proc Natl Acad Sci U S A 2000;97:12407-8.
20. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, et al. Suppression of aging in mice by the hormone Klotho. Science 2005;309:1829-33.
21. Tatar M, Bartke A, Antebi A. The endocrine regulation of aging by insulin-like signals. Science 2003;299:1346-51.
22. Kawano K, Ogata N, Chiano M, Molloy H, Kleyn P, Spector TD, et al. Klotho gene polymorphisms associated with bone density of aged postmenopausal women. J Bone Miner Res 2002;17:1744-51.
23. Ogata N, Matsumura Y, Shiraki M, Kawano K, Koshizuka Y, Hosoi T, et al. Association of klotho gene polymorphism with bone density and spondylosis of the lumbar spine in postmenopausal women. Bone 2002;31:37-42.
24. Yamada Y, Ando F, Niino N, Shimokata H. Association of polymorphisms of the androgen receptor and klotho genes with bone mineral density in Japanese women. J Mol Med 2005;83:50-7.
25. Arking DE, Krebsova A, Macek M Sr, Macek M Jr, Arking A, Mian IS, et al. Association of human aging with a functional variant of klotho. Proc Natl Acad Sci U S A 2002;99:856-61.
26. Arking DE, Becker DM, Yanek LR, Fallin D, Judge DP, Moy TF, et al. KLOTHO allele status and the risk of early-onset occult coronary artery disease. Am J Hum Genet 2003;72:1154-61.
27. Arking DE, Atzmon G, Arking A, Barzilai N, Dietz HC. Association between a functional variant of the KLOTHO gene and high-density lipoprotein cholesterol, blood pressure, stroke, and longevity. Circ Res 2005;96:412-8.
28. Beresford JN. Osteogenic stem cells and the stromal system of bone and marrow. Clin Orthop 1989;240:270-80.
29. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999;284:143-7.
30. Bennett JH, Joyner CJ, Triffitt JT, Owen ME. Adipocytic cells cultured from marrow have osteogenic potential. J Cell Sci 1991;99:131-9.
31. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-56.
32. Meunier P, Aaron J, Edouard C, Vignon G. Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies. Clin Orthop 1971;80:147-54.
33. Burkhardt R, Kettner G, Bohm W, Schmidmeier M, Schlag R, Frisch B, et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: a comparative histomorphometric study. Bone 1987;8:157-64.
34. Rozman C, Feliu E, Berga L, Reverter JC, Climent C, Ferran MJ. Age-related variations of fat tissue fraction in normal human bone marrow depend both on size and number of adipocytes: a stereological study. Exp Hematol 1989;17:34-7.
35. Akune T, Ohba S, Kamekura S, Yamaguchi M, Chung U, Kubota N, et al. PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113:846-55.
36. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, et al. PPARγ gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999;4:597-609.
37. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 2000;106:459-65.
38. Ogawa S, Urano T, Hosoi T, Miyao M, Hoshino S, Fujita M, et al. Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor gamma gene: PPARγ-gamma expression in osteoblasts. Biochem Biophys Res Commun 1999;260:122-6.
39. Koutnikova H, Cock TA, Watanabe M, Houten SM, Champy MF, Dierich A, et al. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPARγ gamma hypomorphic mice. Proc Natl Acad Sci U S A 2003;100:14457-62.
40. hyp/hyp mice relocates haematopoiesis to the spleen. EMBO Rep 2004;5:1007-12.
41. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207.
42. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305-17.
43. Berner HS, Lyngstadaas SP, Spahr A, Monjo M, Thommesen L, Drevon CA, et al. Adiponectin and its receptors are expressed in bone-forming cells. Bone 2004;35:842-9.
44. Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, et al. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone 2003;33:646-51.
45. Shinoda Y, Yamaguchi M, Ogata N, Akune T, Kubota N, Yamauchi T, et al. Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways. J Cell Biochem 2006;99(1):196-208.
46. Kadowaki T, Tobe K, Honda-Yamamoto R, Tamemoto H, Kaburagi Y, Momomura K, et al. Signal transduction mechanism of insulin and insulin-like growth factor-1. Endocr J 1996;43:S33-41.
47. Ogata N, Chikazu D, Kubota N, Terauchi Y, Tobe T, Azuma Y, et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest 2000;105:935-43.
48. Akune T, Hoshi K, Kubota Y, Terauchi K, Tobe Y, Azuma T, et al. Insulin receptor substrate-2 maintains predominance of anabolic function over catabolic function of osteoblasts. J Cell Biol 2002;159:147-56.